Lumos Pharma Inc LUMO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if LUMO is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $2.76
- Day Range
- $2.74–2.78
- 52-Week Range
- $2.41–4.55
- Bid/Ask
- $2.78 / $2.98
- Market Cap
- $22.48 Mil
- Volume/Avg
- 688 / 19,787
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 11.10
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- 2.60%
Company Profile
Lumos Pharma Inc is a biopharmaceutical company that develops treatments for cancer and rare diseases. It carries out both clinical-stage and preclinical research on a range of molecules that help the immune system fight off cancer cells. The treatments are available orally and can be used in conjunction with other cancer therapies. The company also researches an Ebola vaccine. Lumos contracts with manufacturing organizations to make their treatments, engages in partnerships with pharmaceutical companies, and operates in the United States.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 33
- Website
- https://www.lumos-pharma.com
Valuation
|
Metric
|
LUMO
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.83 |
Price/Sales | 11.10 |
Price/Cash Flow | — |
Price/Earnings
LUMO
Financial Strength
|
Metric
|
LUMO
|
|---|---|
Quick Ratio | 5.16 |
Current Ratio | 5.69 |
Interest Coverage | — |
Quick Ratio
LUMO
Profitability
|
Metric
|
LUMO
|
|---|---|
Return on Assets (Normalized) | −56.47% |
Return on Equity (Normalized) | −72.55% |
Return on Invested Capital (Normalized) | −76.18% |
Return on Assets
LUMO
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Pxsclypdt | Rkx | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Spvcmzwt | Mzwgcrm | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Sxwxgkfmt | Vmqhb | $97.8 Bil | |
MRNA
| Moderna Inc | Tkzcvzgz | Clmr | $41.3 Bil | |
ARGX
| argenx SE ADR | Rqrcjkjlg | Ggyvz | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Nmdftmbf | Knrfz | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Jwkqzhlyj | Jbmmfkr | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Jtvzrcnk | Dwjwpr | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Gkvrfcmns | Gnzjwz | $12.5 Bil | |
INCY
| Incyte Corp | Hqjkrrmll | Kkwlyks | $11.6 Bil |